Molecular-Based Score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome

Autor(es)

Coelho-Silva, Juan L. ^{[1, 2]} ; Silveira, Douglas R. A. ^{[3, 4]} ; Pereira-Martins, Diego A. ^{[5, 2]} ; Rojas, Cesar A. O. ^[2] ; Lucena-Araujo, Antonio R. ^[6] ; Rego, Eduardo M. ^{[2, 3]} ; Machado-Neto, Joao A. ^[7] ; Bendit, Israel ^[3] ; Rocha, Vanderson ^[3] ; Traina, Fabiola ^{[1, 2]}

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Ribeirao Preto Med Sch, Ribeirao Preto, SP - Brazil

^[2] Sao Paulo Res Fdn, Ctr Cell Based Therapy, Ribeirao Preto, SP - Brazil

^[3] Univ Sao Paulo, Fac Med, Hematol Div, LIM31, Sao Paulo, SP - Brazil

^[4] AC Camargo Canc Ctr, Dept Haematol, Sao Paulo - Brazil

^[5] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Internal Med, Ribeirao Preto, SP - Brazil

^[6] Univ Fed Pernambuco, Dept Genet, Recife, PE - Brazil

^[7] Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, Sao Paulo, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: SCIENTIFIC REPORTS; v. 11, n. 1 JAN 18 2021.
• Citações Web of Science: 0

Resumo

Deregulated cellular energetics is formally incorporated as an emerging hallmark of cancer, however little is known about its processes in myelodysplastic syndromes (MDS). Using transcriptomic data of CD34+ cells from 159 MDS patients and 17 healthy donors, we selected 37 genes involved in cellular energetics and interrogated about its clinical and prognostic functions. Based on the low expression of ACLY, ANPEP, and PANK1, as well as high expression of PKM and SLC25A5, we constructed our Molecular-Based Score (MBS), that efficiently discriminated patients at three risks groups: favourable risk (n=28; 3-year overall survival (OS): 100%); intermediate (n=60; 76% {[}62-93%]) and adverse (n=71; 35% {[}17-61%]). Adverse MBS risk was independently associated with inferior OS (HR=10.1 {[}95% CI 1.26-81]; P=0.029) in multivariable analysis using age, gender and the revised international prognostic score system as confounders. Transcriptional signature revealed that Favourable- and intermediate-risk patients presented enriched molecular programs related to mature myeloid progenitors, cell cycle progression, and oxidative phosphorylation, indicating that this cells differs in their origin, metabolic state, and cell cycle regulation, in comparison to the adverse-risk. Our study provides the first evidence that cellular energetics is transcriptionally deregulated in MDS CD34+ cells and establishes a new useful prognostic score based on the expression of five genes. (AU)

• Processo FAPESP: 14/50947-7 - INCT 2014: em Células Tronco e Terapia Celular no Câncer
• Beneficiário: Dimas Tadeu Covas
• Linha de fomento: Auxílio à Pesquisa - Temático
• Processo FAPESP: 17/23117-1 - Avaliação da via TP53/TP73 na enxertia de células de leucemia promielocítica aguda em modelo de xenotransplante
• Beneficiário: Diego Antonio Pereira Martins
• Linha de fomento: Bolsas no Brasil - Doutorado
• Processo FAPESP: 13/08135-2 - CTC - Centro de Terapia Celular
• Beneficiário: Dimas Tadeu Covas
• Linha de fomento: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs
• Processo FAPESP: 16/23191-4 - Investigação da Participação de IRS2 na patogênese de neoplasias mieloproliferativas JAK2V617F utilizando modelos murinos
• Beneficiário: Juan Luiz Coelho da Silva
• Linha de fomento: Bolsas no Brasil - Doutorado
• Processo FAPESP: 17/19864-6 - Investigação da participação das proteínas IRS1 e IRS2 na hematopoese normal e síndrome mielodisplásica utilizando modelos murinos e células-tronco hematopoéticas humanas
• Beneficiário: Fabíola Traina
• Linha de fomento: Auxílio à Pesquisa - Regular